Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Current Cardiovascular Imaging Reports
Published in: Current Cardiovascular Imaging Reports 7/2018

01-07-2018 | Cardiac Magnetic Resonance (E Nagel and V Puntmann, Section Editors)

State of the Art in Cardiovascular T2 Mapping: on the Way to a Cardiac Biomarker?

Authors: Sebastian M. Haberkorn, Maximilian Spieker, Christoph Jacoby, Ulrich Flögel, Malte Kelm, Florian Bönner

Published in: Current Cardiovascular Imaging Reports | Issue 7/2018

Login to get access

Abstract

Purpose of Review

Parametric mapping fosters the role of cardiovascular magnetic resonance in its unique capability to evaluate myocardial tissue without the use of contrast agents. While there is a large body of literature highlighting the role of T1 mapping, the role of T2 mapping is less clear. This review aims to address the latest evidences for added clinical value of T2 mapping.

Recent Findings

T2 mapping shows superior diagnostic accuracy in myocarditis, transplant rejection, and cardiac involvement in lupus erythematosus. Moreover, T2 values predict major adverse cardiovascular events in myocarditis and enable therapy monitoring in lupus erythematosus as well as after heart transplantation. In ischemic cardiomyopathy, T2 mapping discriminates acute from chronic injury and provides additional information for patient risk stratification.

Summary

T2 mapping provides a robust, quantifiable non-contrast-enhanced myocardial biomarker. However, there is no standardization in acquisition protocols, which formulates the future need for standardization ahead of multi-center trails.
Literature
1.
von Knobelsdorff-Brenkenhoff F, Schulz-Menger J. Role of cardiovascular magnetic resonance in the guidelines of the European Society of Cardiology. J Cardiovasc Magn Reson. 2016;18:6.CrossRef
2.
Ferreira VM, Piechnik SK, Robson MD, Neubauer S, Karamitsos TD. Myocardial tissue characterization by magnetic resonance imaging: novel applications of T1 and T2 mapping. J Thorac Imaging. 2014;29(3):147–54.CrossRefPubMedPubMedCentral
3.
Kim RJ, Fieno DS, Parrish TB, Harris K, Chen EL, Simonetti O, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation. 1999;100(19):1992–2002.CrossRefPubMed
4.
Grani C, et al. Prognostic value of cardiac magnetic resonance tissue characterization in risk stratifying patients with suspected myocarditis. J Am Coll Cardiol. 2017;70(16):1964–76.CrossRefPubMed
5.
Kanda T, Fukusato T, Matsuda M, Toyoda K, Oba H, Kotoku J’, et al. Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy. Radiology. 2015;276(1):228–32.CrossRefPubMed
6.
Nassenstein K, et al. Cardiac MRI: T2-mapping versus T2-weighted dark-blood TSE imaging for myocardial edema visualization in acute myocardial infarction. Rofo. 2014;186(2):166–72.PubMed
7.
Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper LT, et al. Cardiovascular magnetic resonance in myocarditis: a JACC White Paper. J Am Coll Cardiol. 2009;53(17):1475–87.CrossRefPubMedPubMedCentral
8.
Park CH, Choi EY, Kwon HM, Hong BK, Lee BK, Yoon YW, et al. Quantitative T2 mapping for detecting myocardial edema after reperfusion of myocardial infarction: validation and comparison with T2-weighted images. Int J Cardiovasc Imaging. 2013;29(Suppl 1):65–72.CrossRefPubMed
9.
Messroghli DR, Radjenovic A, Kozerke S, Higgins DM, Sivananthan MU, Ridgway JP. Modified look-locker inversion recovery (MOLLI) for high-resolution T1 mapping of the heart. Magn Reson Med. 2004;52(1):141–6.CrossRefPubMed
10.
Roller FC, Harth S, Schneider C, Krombach GA. T1, T2 mapping and extracellular volume fraction (ECV): application, value and further perspectives in myocardial inflammation and cardiomyopathies. Rofo: Fortschritte Auf Dem Gebiete Der Rontgenstrahlen Und Der Nuklearmedizin. 2015;187(9):760–70.CrossRefPubMed
11.
• Messroghli, D.R., et al., Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI). J Cardiovasc Magn Reson, 2017. 19(1): p. 75. European consensus statement.
12.
Perea Palazón RJ, et al. Parametric methods for characterizing myocardial tissue by magnetic resonance imaging (part 2): T2 mapping. Australas Radiol. 2015;57(6):471–9.
13.
Higgins CB, Herfkens R, J. Lipton M, Sievers R, Sheldon P, Kaufman L, et al. Nuclear magnetic resonance imaging of acute myocardial infarction in dogs: alterations in magnetic relaxation times. Am J Cardiol. 1983;52(1):184–8.CrossRefPubMed
14.
Thavendiranathan P, Walls M, Giri S, Verhaert D, Rajagopalan S, Moore S, et al. Improved detection of myocardial involvement in acute inflammatory cardiomyopathies using T2 mapping. Circ Cardiovasc Imaging. 2012;5(1):102–10.CrossRefPubMed
15.
16.
McNamara MT, Higgins CB, Schechtmann N, Botvinick E, Lipton MJ, Chatterjee K, et al. Detection and characterization of acute myocardial infarction in man with use of gated magnetic resonance. Circulation. 1985;71(4):717–24.CrossRefPubMed
17.
Giri S, Chung YC, Merchant A, Mihai G, Rajagopalan S, Raman SV, et al. T2 quantification for improved detection of myocardial edema. J Cardiovasc Magn Reson. 2009;11:56.CrossRefPubMedPubMedCentral
18.
Sprinkart AM, Luetkens JA, Träber F, Doerner J, Gieseke J, Schnackenburg B, et al. Gradient spin echo (GraSE) imaging for fast myocardial T2 mapping. J Cardiovasc Magn Reson. 2015;17:12.CrossRefPubMedPubMedCentral
19.
Foltz WD, al-Kwifi O, Sussman MS, Stainsby JA, Wright GA. Optimized spiral imaging for measurement of myocardial T2 relaxation. Magn Reson Med. 2003;49(6):1089–97.CrossRefPubMed
20.
21.
• Baessler, B., et al., A systematic evaluation of three different cardiac T2-mapping sequences at 1.5 and 3T in healthy volunteers. Eur J Radiol, 2015. 84(11): p. 2161–70. Systematic evaluation of different T2 mapping seuqnces.
22.
Verhaert D, Thavendiranathan P, Giri S, Mihai G, Rajagopalan S, Simonetti OP, et al. Direct T2 quantification of myocardial edema in acute ischemic injury. JACC Cardiovasc Imaging. 2011;4(3):269–78.CrossRefPubMedPubMedCentral
23.
Tahir E, Sinn M, Bohnen S, Avanesov M, Säring D, Stehning C, et al. Acute versus chronic myocardial infarction: diagnostic accuracy of quantitative native T1 and T2 mapping versus assessment of edema on standard T2-weighted cardiovascular MR images for differentiation. Radiology. 2017;285(1):83–91.CrossRefPubMed
24.
Carberry J, Carrick D, Haig C, Ahmed N, Mordi I, McEntegart M, et al. Persistence of infarct zone T2 hyperintensity at 6 months after acute ST-segment-elevation myocardial infarction: incidence, pathophysiology, and prognostic implications. Circ Cardiovasc Imaging. 2017;10(12):e006586.CrossRefPubMedPubMedCentral
25.
Layland J, Rauhalammi S, Lee MMY, Ahmed N, Carberry J, Teng Yue May V, et al. Diagnostic accuracy of 3.0-T magnetic resonance T1 and T2 mapping and T2-weighted dark-blood imaging for the infarct-related coronary artery in non-ST-segment elevation myocardial infarction. J Am Heart Assoc. 2017;6(4):e004759.CrossRefPubMedPubMedCentral
26.
Giustino G, Chieffo A, Palmerini T, Valgimigli M, Feres F, Abizaid A, et al. Efficacy and safety of dual antiplatelet therapy after complex PCI. J Am Coll Cardiol. 2016;68(17):1851–64.CrossRefPubMed
27.
Varma N, Hinojar R, D’Cruz D, Arroyo Ucar E, Indermuehle A, Peel S, et al. Coronary vessel wall contrast enhancement imaging as a potential direct marker of coronary involvement: integration of findings from CAD and SLE patients. JACC Cardiovasc Imaging. 2014;7(8):762–70.CrossRefPubMedPubMedCentral
28.
Robbers L, et al. The influence of microvascular injury on native T1 and T2* relaxation values after acute myocardial infarction: implications for non-contrast-enhanced infarct assessment. Eur Radiol. 2018;28(2):824–32.CrossRefPubMed
29.
30.
O’Regan DP, Ahmed R, Karunanithy N, Neuwirth C, Tan Y, Durighel G, et al. Reperfusion hemorrhage following acute myocardial infarction: assessment with T2* mapping and effect on measuring the area at risk. Radiology. 2009;250(3):916–22.CrossRefPubMed
31.
Langhans B, Nadjiri J, Jähnichen C, Kastrati A, Martinoff S, Hadamitzky M. Reproducibility of area at risk assessment in acute myocardial infarction by T1- and T2-mapping sequences in cardiac magnetic resonance imaging in comparison to Tc99m-sestamibi SPECT. Int J Cardiovasc Imaging. 2014;30(7):1357–63.CrossRefPubMed
32.
Ugander M, Bagi PS, Oki AJ, Chen B, Hsu LY, Aletras AH, et al. Myocardial edema as detected by pre-contrast T1 and T2 CMR delineates area at risk associated with acute myocardial infarction. JACC Cardiovasc Imaging. 2012;5(6):596–603.CrossRefPubMedPubMedCentral
33.
•• Fernandez-Jimenez R, et al. Dynamic edematous response of the human heart to myocardial infarction: implications for assessing myocardial area at risk and salvage. Circulation. 2017;136(14):1288–300. First in vivo longitudinal analysis of myocardial edema.CrossRefPubMedPubMedCentral
34•.
Carrick, D., et al., Prognostic significance of infarct core pathology revealed by quantitative non-contrast in comparison with contrast cardiac magnetic resonance imaging in reperfused ST-elevation myocardial infarction survivors. Eur Heart J, 2016. 37(13): p. 1044–59. Prognostic value of CMR mapping.
35.
36.
Bulluck H, White SK, Rosmini S, Bhuva A, Treibel TA, Fontana M, et al. T1 mapping and T2 mapping at 3T for quantifying the area-at-risk in reperfused STEMI patients. J Cardiovasc Magn Reson. 2015;17:73.CrossRefPubMedPubMedCentral
37.
38.
Mayr A, Klug G, Feistritzer HJ, Reinstadler SJ, Reindl M, Esterhammer R, et al. Myocardial edema in acute myocarditis: relationship of T2 relaxometry and late enhancement burden by using dual-contrast turbo spin-echo MRI. Int J Cardiovasc Imaging. 2017;33(11):1789–94.CrossRefPubMedPubMedCentral
39.
Lurz P, Luecke C, Eitel I, Föhrenbach F, Frank C, Grothoff M, et al. Comprehensive cardiac magnetic resonance imaging in patients with suspected myocarditis: The MyoRacer-Trial. J Am Coll Cardiol. 2016;67(15):1800–11.CrossRefPubMed
40.
• Bonner, F., et al., Myocardial T2 mapping increases noninvasive diagnostic accuracy for biopsy-proven myocarditis. JACC Cardiovasc Imaging, 2016. 9(12): p. 1467–1469. Diagnostic accuracy of T2 mapping in acute myocarditis.
41.
Bohnen S, Radunski UK, Lund GK, Kandolf R, Stehning C, Schnackenburg B, et al. Performance of t1 and t2 mapping cardiovascular magnetic resonance to detect active myocarditis in patients with recent-onset heart failure. Circ Cardiovasc Imaging. 2015;8(6):e003073.CrossRefPubMed
42.
Baessler B, et al. A novel multiparametric imaging approach to acute myocarditis using T2-mapping and CMR feature tracking. J Cardiovasc Magn Reson. 2017;19(1):71.CrossRefPubMedPubMedCentral
43.
Baessler B, et al. Re-evaluation of a novel approach for quantitative myocardial oedema detection by analysing tissue inhomogeneity in acute myocarditis using T2-mapping. Eur Radiol. 2017;27(12):5169–78.CrossRefPubMed
44.
Baessler B, et al. Mapping tissue inhomogeneity in acute myocarditis: a novel analytical approach to quantitative myocardial edema imaging by T2-mapping. J Cardiovasc Magn Reson. 2015;17:115.CrossRefPubMedPubMedCentral
45.
Mavrogeni S, Schwitter J, van Rossum A, Nijveldt R, Aletras A, Kolovou G, et al. Cardiac magnetic resonance imaging in myocardial inflammation in autoimmune rheumatic diseases: an appraisal of the diagnostic strengths and limitations of the Lake Louise criteria. Int J Cardiol. 2018;252:216–9.CrossRefPubMed
46.
Luetkens JA, Homsi R, Sprinkart AM, Doerner J, Dabir D, Kuetting DL, et al. Incremental value of quantitative CMR including parametric mapping for the diagnosis of acute myocarditis. Eur Heart J Cardiovasc Imaging. 2016;17(2):154–61.CrossRefPubMed
47.
Kim PK, Hong YJ, Im DJ, Suh YJ, Park CH, Kim JY, et al. Myocardial T1 and T2 mapping: techniques and clinical applications. Korean J Radiol. 2017;18(1):113–31.CrossRefPubMedPubMedCentral
48.
Ferreira VM, Piechnik SK, Dall'Armellina E, Karamitsos TD, Francis JM, Ntusi N, et al. T(1) mapping for the diagnosis of acute myocarditis using CMR: comparison to T2-weighted and late gadolinium enhanced imaging. JACC Cardiovasc Imaging. 2013;6(10):1048–58.CrossRefPubMed
49.
•• Spieker, M., et al., Abnormal T2 mapping cardiovascular magnetic resonance correlates with adverse clinical outcome in patients with suspected acute myocarditis. J Cardiovasc Magn Reson, 2017. 19(1): p. 38. Prognostic value of T2 mapping in acute myocarditis.
50.
Bohnen S, Radunski UK, Lund GK, Ojeda F, Looft Y, Senel M, et al. Tissue characterization by T1 and T2 mapping cardiovascular magnetic resonance imaging to monitor myocardial inflammation in healing myocarditis. Eur Heart J Cardiovasc Imaging. 2017;18(7):744–51.CrossRefPubMed
51.
Luetkens JA, Homsi R, Dabir D, Kuetting DL, Marx C, Doerner J, et al. Comprehensive cardiac magnetic resonance for short-term follow-up in acute myocarditis. J Am Heart Assoc. 2016;5(7):e003603.CrossRefPubMedPubMedCentral
52.
Radunski UK, Lund GK, Säring D, Bohnen S, Stehning C, Schnackenburg B, et al. T1 and T2 mapping cardiovascular magnetic resonance imaging techniques reveal unapparent myocardial injury in patients with myocarditis. Clin Res Cardiol. 2017;106(1):10–7.CrossRefPubMed
53.
Puntmann VO, Voigt T, Chen Z, Mayr M, Karim R, Rhode K, et al. Native T1 mapping in differentiation of normal myocardium from diffuse disease in hypertrophic and dilated cardiomyopathy. JACC Cardiovasc Imaging. 2013;6:475–84.CrossRefPubMed
54.
Assomull RG, Prasad SK, Lyne J, Smith G, Burman ED, Khan M, et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol. 2006;48(10):1977–85.CrossRefPubMed
55.
Kawai C. From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death: learning from the past for the future. Circulation. 1999;99(8):1091–100.CrossRefPubMed
56.
Halliday BP, Gulati A, Ali A, Guha K, Newsome S, Arzanauskaite M, et al. Association between midwall late gadolinium enhancement and sudden cardiac death in patients with dilated cardiomyopathy and mild and moderate left ventricular systolic dysfunction. Circulation. 2017;135(22):2106–15.CrossRefPubMedPubMedCentral
57.
Nishii T, Kono AK, Shigeru M, Takamine S, Fujiwara S, Kyotani K, et al. Cardiovascular magnetic resonance T2 mapping can detect myocardial edema in idiopathic dilated cardiomyopathy. Int J Cardiovasc Imaging. 2014;30(Suppl 1):65–72.CrossRefPubMed
58.
Ito T, K. Kono A, Takamine S, Shigeru M, Mori S, Takaya T, et al. A comparison of quantitative T2 mapping on cardiovascular magnetic resonance imaging with metaiodobenzylguanidine scintigraphy and left ventricular functional recovery in dilated cardiomyopathy: a retrospective pilot study. Intern Med. 2015;54(17):2121–8.CrossRefPubMed
59.
Nakayama T, Sugano Y, Yokokawa T, Nagai T, Matsuyama TA, Ohta-Ogo K, et al. Clinical impact of the presence of macrophages in endomyocardial biopsies of patients with dilated cardiomyopathy. Eur J Heart Fail. 2017;19(4):490–8.CrossRefPubMed
60.
Kono AK, Croisille P, Nishii T, Nishiyama K, Kyotani K, Shigeru M, et al. Cardiovascular magnetic resonance tagging imaging correlates with myocardial dysfunction and T2 mapping in idiopathic dilated cardiomyopathy. Int J Cardiovasc Imaging. 2014;30(Suppl 2):145–52.CrossRefPubMed
61.
Mordi I, Carrick D, Bezerra H, Tzemos N. T1 and T2 mapping for early diagnosis of dilated non-ischaemic cardiomyopathy in middle-aged patients and differentiation from normal physiological adaptation. Eur Heart J Cardiovasc Imaging. 2016;17(7):797–803.CrossRefPubMed
62.
Butler CR, Thompson R, Haykowsky M, Toma M, Paterson I. Cardiovascular magnetic resonance in the diagnosis of acute heart transplant rejection: a review. J Cardiovasc Magn Reson. 2009;11:7.CrossRefPubMedPubMedCentral
63.
Lund G, Morin RL, Olivari MT, Ring WS. Serial myocardial T2 relaxation time measurements in normal subjects and heart transplant recipients. J Heart Transplant. 1988;7(4):274–9.PubMed
64.
van Heeswijk RB, Piccini D, Tozzi P, Rotman S, Meyer P, Schwitter J, et al. Three-dimensional self-navigated T2 mapping for the detection of acute cellular rejection after orthotopic heart transplantation. Transplant Direct. 2017;3(4):e149.CrossRefPubMedPubMedCentral
65.
• Usman, A.A., et al., Cardiac magnetic resonance T2 mapping in the monitoring and follow-up of acute cardiac transplant rejection: a pilot study. Circ Cardiovasc Imaging, 2012. 5(6): p. 782–90. Value of T2 mapping as a biomarker.
66.
Tan CD, Baldwin WM 3rd, Rodriguez ER. Update on cardiac transplantation pathology. Arch Pathol Lab Med. 2007;131(8):1169–91.PubMed
67.
Markl M, Rustogi R, Galizia M, Goyal A, Collins J, Usman A, et al. Myocardial T2-mapping and velocity mapping: changes in regional left ventricular structure and function after heart transplantation. Magn Reson Med. 2013;70(2):517–26.CrossRefPubMed
68.
•• Hinojar, R., et al., Native T1 and T2 mapping by CMR in lupus myocarditis: disease recognition and response to treatment. Int J Cardiol, 2016. 222: p. 717–26. Relevance of T2 mapping in lupus myocarditis.
69.
Zhang Y, Corona-Villalobos CP, Kiani AN, Eng J, Kamel IR, Zimmerman SL, et al. Myocardial T2 mapping by cardiovascular magnetic resonance reveals subclinical myocardial inflammation in patients with systemic lupus erythematosus. Int J Cardiovasc Imaging. 2015;31(2):389–97.CrossRefPubMed
70.
Greulich S, et al. Comprehensive cardiovascular magnetic resonance assessment in patients with sarcoidosis and preserved left ventricular ejection fraction. Circ Cardiovasc Imaging. 2016;9(11)
71.
Puntmann VO, Isted A, Hinojar R, Foote L, Carr-White G, Nagel E. T1 and T2 mapping in recognition of early cardiac involvement in systemic sarcoidosis. Radiology. 2017;285(1):63–72.CrossRefPubMed
72.
Greulich S, Mayr A, Kitterer D, Latus J, Henes J, Steubing H, et al. T1 and T2 mapping for evaluation of myocardial involvement in patients with ANCA-associated vasculitides. J Cardiovasc Magn Reson. 2017;19(1):6.CrossRefPubMedPubMedCentral
73.
Holmstrom M, et al. Cardiac magnetic resonance imaging reveals frequent myocardial involvement and dysfunction in active rheumatoid arthritis. Clin Exp Rheumatol. 2016;34(3):416–23.PubMed
74.
Greulich S, Mayr A, Kitterer D, Latus J, Henes J, Vecchio F, et al. Advanced myocardial tissue characterisation by a multi-component CMR protocol in patients with rheumatoid arthritis. Eur Radiol. 2017;27(11):4639–49.CrossRefPubMedPubMedCentral
75.
Gerster M, Peker E, Nagel E, Puntmann VO. Deciphering cardiac involvement in systemic inflammatory diseases: noninvasive tissue characterisation using cardiac magnetic resonance is key to improved patients’ care. Expert Rev Cardiovasc Ther. 2016;14(11):1283–95.CrossRefPubMed
76.
Zia MI, Ghugre NR, Connelly KA, Strauss BH, Sparkes JD, Dick AJ, et al. Characterizing myocardial edema and hemorrhage using quantitative T2 and T2* mapping at multiple time intervals post ST-segment elevation myocardial infarction. Circ Cardiovasc Imaging. 2012;5(5):566–72.CrossRefPubMed
77.
Kvernby S, Warntjes MJB, Haraldsson H, Carlhäll CJ, Engvall J, Ebbers T. Simultaneous three-dimensional myocardial T1 and T2 mapping in one breath hold with 3D-QALAS. J Cardiovasc Magn Reson. 2014;16:102.CrossRefPubMedPubMedCentral
Metadata
Title
State of the Art in Cardiovascular T2 Mapping: on the Way to a Cardiac Biomarker?
Authors
Sebastian M. Haberkorn
Maximilian Spieker
Christoph Jacoby
Ulrich Flögel
Malte Kelm
Florian Bönner
Publication date
01-07-2018
Publisher
Springer US
Published in
Current Cardiovascular Imaging Reports / Issue 7/2018
Print ISSN: 1941-9066
Electronic ISSN: 1941-9074
DOI
https://doi.org/10.1007/s12410-018-9455-3

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24 to hear Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits